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INTRODUCTION

Several chemical mediators play an important role
in the normal functioning of the respiratory system in
man,

in addition to the expression of the immune response.

These mediators include histamine,
krein,

prostaglandins,

kalli-

eosinophil chemotactic factor of anaphylaxis

(ECF-A),

slow-reacting factor of anaphylaxis

and platelet-activating factor (PAF).

(SRS-A),

All may be released

by normal respiratory tissue after passive sensitization
with IgE antibody and

challenge

with

specific

anti¬

gen (8) .
Mediators may be released from cells such as mast
cells and basophils in response to a number of immuno¬
logic or non-specofic stimuli.
stimuli

include histamine,

bradykinin,
cold air,
(15)•

Airway-constricting

cholinergic agonists, SRS-A,

prostaglandin F 2oc» 3-adrenergic blocking drugs ,

dust,

sulfur dioxide,

exercise,

and suggestion

In addition to their role in normal physiologic

processes,

mediators play an important role in the patho¬

genesis of disease states such as asthma and the anaphyl¬
actic response.
The following pages will focus on histamine,
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a

well-investigated mediator.

The actions and role of

histamine in both the normal and pathologic setting
will be addressed.

There will be particular focus on

the presence of histamine in the respiratory system.
The final chapter includes an original investigation
of the presence of histamine receptors in the airways
of healthy,

human subjects.

HISTAMINE
Background and History
Histamine, 3-imidazolylethylamine,
synthesized in the laboratory in 1907.

was first
Ln vivo,

it

is formed by the decarboxylation of L-histidine, by
histidine decarboxylase.

Histamine was first isolated

in bacteria in 1910 and was one of the first vaso¬
active substances to be identified

(42, 43).

The

name is derived from the Greek word histos, meaning
tissue.
Histamine is stored in mast cells in various
tissues as well as in basophils in blood.
cell, which also contains heparin,
tory for histamine.

The mast

is the major reposi¬

Histamine is also present in as

yet unidentified non-mast cells of the gastric and
intestinal mucosa and the brain.

In the rabbit (12),

the

bulk of histamine in the blood is stored in the platelets.
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Histamine is released in response to various
immunological stimuli as in IgE-antigen-mediated immune
reactions (lL).

It is also released in response to

nonimmunological stimuli such as trauma,
suggestion (131)-

toxins,

or

The liberation of histamine by cells

in response to injurious stimuli was noted as early as
1Q27 by Lewis (52).
and anaphylatoxin,

Mast cell liberators,

such as dextran

may also release histamine.

During the release of histamine from mast cells,
the mast cell degranulates.
ule,

The histamine stored in the gran¬

along with other preformed and stored mediators,

is ex-

pulsed from the cell and is followed by release of
histamine from a heparin-protein complex (12).
polar molecule at physiologic pH,

A highly

histamine does not

diffuse across the blood-brain barrier or cell membranes.
The action of histamine is rapid.

It quickly

diffuses into tissues and is rapidly metabolized.

Gut

flora in man converts ingested histamine to the inactive
N-acetylhistamine (52).

Once released,

histamine will

disappear from the blood stream within minutes.
Histamine and Its Receptors
Histamine exerts its effects through interaction
with at least two identifiable receptors, which are
referred to as Ha and H2 receptors.
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These receptors

may be preferentially blocked by specific antihistamines
The Hi

class of antihistamines are referred to as the

"classical antihistamines".

The first antihistamines

to be developed, Bovet and Staub discovered the first
Hi antihistamines in 1937*
AriVs' X —C — C —

where X may be C,

0,

The structure is of the form

CH3
\ CH3

or N, Ari and Ar2 are aromatic or

aryl ring structures and N must be charged at physio¬
logic pH.

Antihistamines act by competitive and re¬

versible occupation of histamine receptor sites without
themselves initiating a response.
Ash and Schild

(6) were the first to demonstrate

the presence of more than one class of histamine recep¬
tor.

They demonstrated that several effects of hista¬

mine,

such as stimulation of gastric secretion and

inhibition of rat uterus contractions could not be
suppressed by classical antihistamines.
Black, _et al.
burimamide,

(18) were the first to develop

an H2 receptor antagonist.

It was noted

that while burimamide did not have any significant Hi
receptor antagonism,

it successfully prevented gastric

acid secretion.
Further evidence for the existence of two separate
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classes of histamine receptors has come from the syn¬
thesis of agonists specific to Ha and H2 receptors.
For example, while 2-methylhistamine can elicit the Hi
effect of stimulating bronchial contraction,
significant effect on gastric acid secretion.
other hand,
secretion,
(52).

it has no
On the

4-methylhistamine can increase gastric acid
but has little effect on airway constriction

In one study (18),

2-methylhistamine was shown

to have 16.5$ of the Hi activity of histamine as
measured by ability to constrict guinea pig terminal
ileum.

Its H2-mediated ability to stimulate isolated

atrium was only 4.4%.

While 4-methyhistamine had 43%

of the ability of histamine to stimulate the guinea
pig isolated atria,

the relative activity on terminal

ileum was only 0.23%.
Other Hi agonists include 2-(2-aminoethyl)-pyridine
and 2-(2-aminoethyl)-thiazole (125).
are clonidine (7), St 600

Other H£ agonists

([2-(5~flouro-o-toluidine)-2

imidazoline hydrochloride])(27),

and dimaprit ([S-[3-

(N,N-dimethyamino)propyl]isothiourea])(121).
THE ACTIONS AND ROLE OF HISTAMINE AND
ANTIHISTAMINES IN PHYSIOLOGIC PROCESSES
Histamine was recognized a half-century ago (11)
as being involved in the inflammatory response and
allergic phenomena.

The "classic" histamine response
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in man includes itching,
flush),

headache,

swelling,

redness (histamine

and bronchoconstriction.

will elicit the cutaneous "triple response"
spot and flush, wheal,

Histamine
of a red

and itch--symptoms which are

associated with the inflammatory response and anaphyl¬
axis.

The following are brief outlines of some other

actions of histamine, with emphasis,

where possible,

of the pharmacologic effects of histamine and anti¬
histamines in man.

The role of histamine in the immune

response and pathologic processes will be dealt with in
greater detail in a subsequent chapter.
Respiratory System
In man,

large concentrations of histamine have the

primary effect of bronchoconstriction.

Histamine causes

an increase in respiratory air resistance and a decrease
in airway compliance (8).

Other animal species may

exhibit either bronchoconstriction,
or both in response to histamine.

bronchodilation,
The response will

be determined by which part of the respiratory system
is stimulated,

which specific receptors are agonized,

and what are the effects of those specific receptors.
This will be examined in a forthcoming section.
Circulatory System
As in the respiratory system, vasodilation or
vasoconstriction will be the effect of histamine agonism,
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and will vary depending upon the size and location of
the blood vessel,

the classification of histamine recep¬

tor which is being agonized,
involved.

In man,

as well as the species

histamine will cause constriction

of large arteries and veins and dilation of the smallest
vessels to contain smooth muscle.
amine in man,

cats,

dogs,

Intravenous hist¬

and sheep will cause a fall

in systemic blood pressure secondary to peripheral
vasodilation (1,
In cats,

19).

dogs,

and chickens,

the blood vessels

dilate in response to both Hi and H2 agonism (19.
1^5).

34,

In rabbit blood vessels, Ha agonism causes

vasoconstriction and H2 agonism causes vasodilation (34).
The reverse is the case for calves (34,
In man,

66).

peripheral vasodilation is mediated by

both Ha and H2 receptors (l4,

99)-

Combinations of Hi

and H2 antagonists are more successful in preventing
the effects of histamine on skin (101)
vascular system (13)*

and the cardio¬

than use of any one antagonist

alone.
Vasodilation in the cerebral blood vessels in man
accounts for histamine-induced headache.
Histamine's

evanescent effect on small blood

vessel dilation leads to enhancement of the body's
microcirculation, which is due,
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in part,

to the con-

tinuous alternating vasodilation and vasoconstriction
caused by changing concentrations of histamine.

Hist¬

amine will increase capillary permeability with the
resultant effect of formation of edema,
viscosity,

increased blood

and hemoconcentration.

The effect on the heart is to stimulate cardiac
contractility.

Histamine will also increase the rate

of cardiac contraction,
duction.

and will decrease AV-node con¬

In vitro studies of the guinea pig heart (92)

show that Hi receptors may be involved in mediation of
a negative dromotropic effect,
effect,

an atrial inotropic

and promotion of histamine-induced arrythmias

of conduction.

H2 receptors mediate positive chrono¬

tropic effects, ventricular inotropic effects,

and

promote histamine-induced arrythmias of automaticity.
Histamine will constrict smooth muscle of the
spleen.
Endocrine system
The adrenal medulla will release catecholamines
in response to histamine.
Tissue Growth and Repair
Histamine is found in increased concentration in
areas of wound repair.

Increased levels of histamine

may be found in regenerating liver,
and the fetus.

granulation tissue,

Tissue damage through local irritants
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will increase histidine decarboxylase activity at the
site on injury,
(12).

leading to increased histamine levels

Histamine promotes wound healing as well as the

formation of keloids and scar tissue.

It also helps

to provide an increased blood supply to areas of injury.
Gastrointestinal system
Acting through stimulation of H2 receptors,
histamine stimulates gastric acid secretion by the
parietal cells of the stomach.

H2 receptor blockade,

in addition to blocking gastric acid secretion,
blocks the effects of gastrin and pentagastrin.

also
This

finding suggests that histamine may act as a final
"common messenger" for several hormones in the gastric
mucosa (34).
receptors,
( 34).

Histamine may also stimulate, via H2

pancreatic secretion and cholecystokinesis

It will also contract smooth muscle of the gut

via Ha receptor stimulation.
Nervous system
The function of histamine in the brain remains
obscure,

although its presence has been demonstrated

in a variety of structures.

The binding of radio¬

active H2 antagonists has been demonstrated in guinea
pig midbrain,

cortex,

hippocampus,

hypothalamus,

cerebellum,

thalamus,

brainstem,

and corpus striatum (23)-

Histamine has been isolated in rat,
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mouse,

and monkey

hypothalamus as well as midbrain,
(13)*

cortex,

and cerebellum

Histamine agonism with the H2 receptor increases

levels of cyclic AMP in these structures

(l4).

Histamine stimulates sensory nerve endings,
ducing pruritis.

pro¬

Histamine may facilitate ganglionic

transmission via Ha agonism.

H2 receptors may inhibit

ganglionic transmission.
Urinary system
Histamine has a dual mode of action in the human
kidney.

It causes a pressor response on renal vascu¬

lature via Ha agonism and a depressor response via H2
agonism.
Hi Antihistamines
Hi antihistamines, which include chlorpheniramine,
diphenhydramine,

and mepyramine,

use in seasonal rhinitis,
pruritides,

hay fever,

are of therapeutic

allergic dermatoses,

insect bites,

blood transfusion reactions,

ivy poisoning,

serum sickness,

reactions to drugs, Menibre's disease,
52).

itching

allergic

and vertigo (13-

They inhibit the histamine-induced increase in

capillary permeability during anaphylaxis.

Hi anti¬

histamines do not completely block anaphylaxis in man
because of the significant contribution of several other
mediators.
Hi antihistamines may also cause somnolence,
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prevent motion sickness,
effect,

provide a mild anticholinergic

and have a mild anesthetic effect.

their mild anticholinergic,
serotonergic activities,

antiadrenergic,

Because of
and anti-

the use of Hi antihistamines

in laboratory investigations has occasionally resulted
in erroneously ascribing cholinergic,

adrenergic,

or

serotonergic effects to histamine.
Hi antihistamines are metabolized by the liver and
degradation products are almost completely excreted
within 24 hours.

Tissues are almost totally free of

Ha. antagonists within 6 hours.
H2 Antihistamines
H2 antihistamines have gained recent wide clinical
use in the treatment of a variety of gastrointestinal
disorders associated with hypersecretion of gastric
acid.

Of particular significance is the recent popu¬

larity of cimetidine in the treatment of duodenal
ulcers.
Another class of histamine antagonist is the mast
cell stabilizer,

such as cromolyn sodium.

which can also inhibit antigen-induced
amine (52), has as its main effect,
release of histamine and SRS-A.

11
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production of hist¬

the prevention of

Cromolyn sodium does

not interact directly with either Hi

-

Cromolyn,

or H2 receptors.

THE PRESENCE AND ROLE OF Hi AND H2
RECEPTORS IN THE RESPIRATORY SYSTEM
The laboratory investigation which will be described
in a forthcoming chapter will

examine the presence of

histamine Hi and H2 receptors in the airways of healthy
human subjects.

The following is a detailed description

of studies which have investigated the presence of
histamine receptors in the respiratory systems of a
variety of species,

both in vivo and in vitro.

Histamine Receptors in Guinea Pig Airways
Guinea pig trachea may be caused to contract due
to antigen-induced anaphylaxis (Schultz-Dale phenomenon).
It was noted almost fifty years ago (11)

that these

contractions are associated with the release of histamine
from guinea pig lung.

The causative effect of histamine

in producing the contractions has been demonstrated by
the partial or complete block of these contractions by
Hi antihistamines

(38,

85)-

The fact that mepyramine

only partially prevents antigen-induced

contractions

indicates the presence of other mediators which cause
tracheal contractility.
Direct stimulation of guinea pig tracheobronchial
tissue by histamine results in a profound net smooth
muscle contraction (52).
histamine-induced

Mepyramine totally blocks

contraction (85).
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Metiamide, which

antagonizes H2 receptors,
contraction.

However,

potentiates histamine-induced

stimulation of Hi receptors by

the specific Ha agonist,

2-methylhistamine,

causes

constriction which is not potentiated by metiamide (117).
It can thus be inferred that histamine causes both Hx
stimulated contraction and H2 stimulated relaxation of
guinea pig tracheobronchial muscle.

Each effect can

be isolated by use of specific antagonists.
The Hx constricting effects and H2 relaxing effects
on guinea pig tracheobronchial muscle can be demonstrated
indirectly through studies with antihistamines.

However,

more direct evidence is available through observation
of the effects of histamine agonists.
mentioned,

As previously

the effect of 2-methylhistamine is to cause

tracheobronchial contraction.
Another Hx agonist is 2-(2-pyridyl)-ethylamine
(2-PEA).

2-PEA will cause contraction of guinea pig

tracheal spirals,

in vitro.

This constriction of tracheal

spirals and parenchymal strips is reversed by dimaprit,
an H2 agonist, which mediates relaxation of the smooth
muscle.

The effect of dimaprit may be blocked by

metiamide ( 5*0 •
In guinea pig bronchial smooth muscle undergoing
ovalbumin antigen-induced anaphylactic contractions,
dimaprit had a significant bronchodilatory effect (32).
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This effect was even more profound than treatment with an
Hi antagonist,

mepyramine.

Direct evidence for histamine Hi receptor presence in
guinea pig lung and other organ systems has come from studies
which trace histamine receptors by radioactively labelling
tissues with [3H]-mepyramine (4l).
Drazan and Schneider (53)

found that histamine induced

constriction in both guinea pig trachea and lung parenchyma.
They discovered that histamine Hi antagonism by mepyramine was
more successful in blocking constriction in lung parenchyma
than in trachea.

This suggests that histamine receptors are

not necessarily distributed evenly in the airways.

There

appears to be a greater number of receptors and/or sensitivity
to the effects of histamine in peripheral airways in the
guinea pig.

A future study involving radioactively-labelled

antagonists in different parts of the respiratory system
would be useful in supporting these findings.
In addition to the effect of the direct interaction of
histamine with its receptors,

histamine receptor agonism may

also cause release of prostaglandins.

These prostaglandins

act as additional mediators of airway reactivity, but do not
act as the final mediators of histamine agonism.

The mecha¬

nism for release of prostaglandins in response to histamine
stimulation involves Hi receptor-cyclic GMP stimulated release
of PGF2a and H2 receptor-cyclic AM? stimulated release of PGE.
Yen,

et al.

(156)

used the presence of prostaglandins
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PGF 2a and PGE as an assay for determining the distribution
of histamine Ha and H2 receptors within the lung.
that the Hi antagonist,

They found

pyrilamine, blocked the histamine-

induced increases in PGF 2CC.

Metiamide diminished the

histamine-induced release of PGE.
The authors found that in response to histamine in guinea
pig trachea,

PGE was present in much greater concentrations

than PGF2a.

In guinea pig peripheral airways,

PGF 2CX was

present in higher concentrations than PGE (156).

The authors

conclude that there might be more H2 receptors in central than
peripheral airways.

They find this conclusion consistent with

the physiologic importance of maintaining the patency of
central airways.

The rapid shifts,

on the other hand,

peripheral airway size through bronchoconstriction,
suggested to maximize ventilation-perfusion ratios
In additional to prostaglandins,

of

has been
(156).

levels of cyclic nucleo¬

tides are a useful assay for determining the presence of
histamine receptors.

In guinea pig lung anaphylaxis,

the

antigen-antibody reaction yields an increase in levels of
cyclic AMP,

cyclic GMP,

and the ratio of cAMP to cGMP.

Pyrilamine inhibits histamine stimulated increases in cyclic
GMP (103).

Burimamide had no effect on cGMP but blocked the

histamine-induced increases in cAMP.
While there may exist different distributions of
Hi and H2 receptors within guinea pig airways, Hi and
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H2 receptors may also differ in sensitivity to histamine.
Yen (155)

showed that in guinea pig peripheral airway

smooth muscles,

concentrations of 10-10- 10-7 M of

histamine caused bronchorelaxation which was blocked
by metiamide.

Hi receptors had the overwhelming response

in concentrations

of greater than 10"^M of histamine

with the resultant contraction blocked by chlorphenir¬
amine.

It appears that H2 receptors are more sensitive

to histamine than Hx receptors,
tions, Hi receptors win out,

but in high concentra¬

probably because of greater

numbers.
The opposite sensitivities to histamine were
observed by Martin and Fertel (102)
tracheal rings.

in guinea pig

They noted that at concentrations of

5 x lCT-M, guinea pig tracheal rings contracted.
at concentrations
relaxed.

of 10-Z+ M of histamine,

However,

the tissue

Consistent with these observations was the

increase in cyclic GMP levels at low histamine concen¬
trations.

Increased cyclic AMP levels were noted at

high concentrations of histamine.

Thus,

in trachea,

there may be greater sensitivity for Ha receptors,

but

greater numbers of H2 receptors.
In addition to the presence of histamine receptors
in guinea pig airway smooth muscle,

the presence of

histamine Hi receptors in guinea pig alveolar macrophages

-16-

has been demonstrated by both agonist and antagonist
studies

(5°)•

Histamine Receptors in the Respiratory System of the
Rat and Ferret:
Possible Presence of a Subclass of
Receptors
Chand and Eyre (34, 40)

have done extensive studies

on the presence and action of histamine receptors in a
number of species.

They determined that ferret trachea

and bronchus both constricted in response to histamine
in vitro.

This contraction of smooth muscle was blocked

by Hi antagonism with mepyramine.

Rat trachea did not

contract in the presence of histamine (40).
Both rat and ferret trachea and bronchi could be
made to contract ijn vitro by exposure to carbachol.
When subsequently exposed to histamine in the presence
of Hi blockade,

the muscles relaxed.

This indicates

that an K2 receptor must have been mediating the tracheobronchorelaxation,

since the Hi receptors were blocked.

Further evidence comes from studies of direct H2-agonism
by 4-methylhistamine which also caused relaxation of
smooth muscle (40).
It is very interesting to note that the relaxation
was not blocked by metiamide,

burimamide,

or cimetidine.

This important finding suggests the presence of a sub¬
class of histamine receptors which are not blocked by
conventional H2 antagonists, yet are stimulated by

-17-

4-methylhistamine and produce relaxation of airway
smooth muscle.

The proposed name for this subclass

of receptors is

or H3 receptors.

More Evidence for Hjstamine3 Receptors:
The Airways of the Rabbit
Using a similar methodology for in vitro studies
as Chand and Eyre

(40), Fleisch and Calkins

(70)

ascertained that histamine induces contraction of
rabbit bronchus.

This effect was blocked by Hx

antagonism with pyrilamine.

Interestingly,

similar experimental conditions,

under

partially contracted

rabbit trachea experienced relaxation in the presence
of histamine.
pyrilamine,
propranalol.

This effect could not be prevented by

burimamide, metiamide,
Thus,

indomethacin,

or

histamine-induced tracheal relaxa¬

tion does not act through Hi,

prostaglandin release

(65. 70).

or 3-adrenergic mechanisms
Chand and Eyre (36)

H2,

also found that partially-

contracted rabbit bronchus relaxed in the presence of
Hi blockade.
metiamide.
(70)

This response was not eliminated by
It is thus proposed that rabbit trachea

and rabbit bronchus (36)

may contain H3

receptors

which mediate smooth muscle relaxation.
It is important to note that,

as in the guinea pig

the airways of the rabbit experienced different effects
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of histamine stimulation,

depending upon whether central

or peripheral airways were being agonized.

Thus,

two

closely associated tissues in the same system can be
pharmacologically distinct.

It is important,

therefore,

to state specifically which tissues in an airway are
being stimulated,

when analyzing the results of a

histamine study or when designing an investigation.
Histamine Receptors in the Horse; A
Possible Animal Mod el of Human Asthma
Using their model of carbachol-induced,
constricted airways,

in vitro,

partially-

Chand and Eyre (37.

39)

determined that histamine or 2-methylhistamine causes
tracheobronchial constriction in the horse.

Mepyramine

prevents this histamine-induced contraction.

H£ agonists

such as 4-methylhistamine and dimaprit caused tracheo¬
bronchial relaxation in this experimental model.

Further

support of H2 stimulation of muscle relaxation comes
from treatment of partially-constricted bronchus in
the presence of Hx blockade.
which could

This results in relaxation,

only be the result of H2 receptor agonism.

The relaxation in horse bronchus was blocked by
metiamide and burimamide.
metiamide,
effect.

cimetidine,

However,

in horse trachea,

and burimamide had no inhibitory

Perhaps horse trachea also has H3

It has been suggested (39)
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receptors.

that the horse may be

a good model for human asthma.
"broken wind",

Horses suffer from

an obstructive respiratory syndrome,

also known as equine pulmonary emphysema, which,
clinically resembles asthma.

Thus,

the clinical use

of H2 agonists in asthma may be worth future investigation.
Hi blockade is only minimally useful in inhibiting
anaphylaxis in the sensitized horse (63).
anaphylaxis,

As in human

histamine is only one of several mediators

which are involved in the anaphylactic response in the
horse.

Of importance is the fact that H2 antagonists

such as metiamide and burimamide potentiate anaphylaxis
in the horse (39)-

H2 antagonists have also been noted

to exacerbate anaphylaxis in adult domestic fowl and
the calf (39).

The mechanism behind this potentiation

and its implications in the clinical setting will be
dealt with in a forthcoming chapter.
Histamine Receptors in Sheep Airways
Using burimamide, Eyre was the first to discover
(14,

6l,

62,

64)

the presence of H2 receptors in

isolated smooth muscle of sheep bronchi.

He found that

histamine causes contraction of trachea and the major
bronchi in sheep.
antihistamines.

This effect may be blocked by Hx
In response to histamine,
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the lesser

bronchi and bronchioles would relax.
be blocked by burimamide (14,

64).

This effect could
Intravenous histamine

results in a net bronchoconstriction in sheep.

The net

effect of inhaled histamine is either bronchodilation
or minimal bronchoconstriction in the sheep (61,

65).

Histamine Receptors in Cat Airways
In i_n vitro cat trachea partially contracted

due

to carbachol,

histamine challenge leads to a net broncho¬

dilation (14,

62,

64,

100).

This effect may be blocked

by a combination of Hi and H2 antagonists in addition
to propranalol.
trachea,

This finding suggests,

that in the cat

histamine acts by both direct action with both

receptors as well as by indirect action through local
catecholamine release to produce relaxation.
The cat bronchus also relaxes in response to
histamine as well as 2-methylhistamine and 4-methylhistamine (35)either Hi

This

effect is not reversed,

or Hs antagonism, 3-blockade,

inhibition,

however, by

or prostaglandin

thereby suggesting an H3 mechanism.

Other investigators (96,
cat bronchus,

in vitro,

123)

found that in the

histamine challenge caused

smooth muscle contraction,

acting via Hi mechanisms

which could be blocked by mepyramine.

Similarly,

antigen-induced contraction could be abolished by
mepyramine in cat bronchial tissue.
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Histamine Receptors in the Canine Respiratory System
Histamine causes bronchoconstriction in vivo in
the dog.

When delivered histamine size is greater than

10 microns,

bronchoconstriction is mostly through a

reflex vagal mechanism.

There is a direct effect of

histamine on smooth muscle receptors if particle size
is less than 0.5 microns (128).
Dixon,

et al.

(51)

4-methylhistamine,

examined the effect of histamine,

cimetidine,

and chlorpheniramine on

total lung resistance and dynamic lung compliance in
anaesthetized dogs.

While histamine caused an increase

in total lung resistance and a decrease in dynamic lung
compliance,
effect.

the H2 agonist 4-methylhistamine had no such

Accordingly,

the Ha antagonist,

blocked the effect of histamine,
no protective effect.

chlorpheniramine

while cimetidine had

The authors conclude that histamine

acts mostly through Hi mechanisms in the dog and causes
airway constriction.

Since dynamic lung compliance and

total lung resistance are particularly useful in
measuring large airways pulmonary function (°8),

perhaps

this conclusion should not be extended to include the
peripheral airways

of canines.

The counterargument is

that at 0.5 microns in diameter,

the histamine particles

were delivered to the peripheral airways (45).
investigators (5.

33.

83.

132,
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153)

Other

have found similar

in vitro and in vivo evidence in peripheral and central
airways of dogs.

The possibility of regional differences

in histamine receptor distribution are similarly supported
by scientific evidence (33)*
Some investigators (153.

15M

have found that

cimetidine tended to increase airway resistance,
suggesting a small H2-mediated bronchodilatory effect
of histamine in the dog lung.
Irvin and Dempsey (82)

On the other hand,

find a minor contribution of

H2-mediated bronchoconsfriction in the peripheral airways
of dogs.

They concur with other authors regarding the

absence of H2 receptors in canine central airways.
As in humans, mepyramine does not completely
block antigen-induced anaphylaxis (33).

suggesting the

role of other mediators such as SRS-A and serotonin in
this response.

Whereas metiamide has been shown to

exacerbate anaphylaxis in the horse,
fowl (39),

calf,

and domestic

the H2 antagonist has no such in vivo effect

in immediate hypersensitivity reactions (33.
in vitro models of canine asthma (5.
sensitized dogs (5),

In ovalbumin-

isolated trachealis muscle con¬

tracted in response to histamine.
by pyrilamine.

33)-

153) or

This was inhibited

H2 blockade with metiamide had no effect.

Of interest is the effect of H2 stimulation on
respiratory secretions, rather than respiratory muscle
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activity.

Cimetidine blocked stimulation of canine

secretory activity in the lung in histamine-induced
asthma.

Chlorpheniramine also had this effect, but

to a smaller extent (153)•

The investigators conclude

that histamine acts to promote canine asthma through
an Hi-mediated muscular effect and an H2-mediated effect
on secretory activity of the respiratory tract (153154).

They propose that H2 antihistamines might have

therapeutic value in decreasing respiratory secretions
in the asthmatic.
Histamine Receptors in the Airways of Rhesus Monkeys
One published investigation of histamine receptors
in the airways of rhesus monkeys examined the effect
of Hi and H2 antagonism on in vivo pulmonary function
(76).

The authors measured peak expiratory flow,

pulmonary resistance,
volume,

dynamic lung compliance,

total

tidal

and respiratory frequency.

The results of the study indicated that pretreat¬
ment with the Hi antagonist diphenhydramine inhibited
histamine-induced bronchoconstriction.

Metiamide

potentiated histamine’s bronchoconstrictory effects
when given prior to histamine challenge (76).

Thus,

this study seems to indicate that histamine causes
bronchoconstriction in the rhesus monkey via Hi agonism.
H2 receptors are present and apparently modulate the
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bronchoconstriction,

perhaps via relaxation of smooth

muscle or by some feedback mechanism.
Histamine Receptors in the Airways of Man
There have been a few recent studies which have
investigated the role of histamine receptors in the
airways of man.

These preliminary reports include

studies of healthy human subjects as well as human
asthmatics, who represent a special class of people
who are exquisitely sensitive to minute quantities of
histamine.
Histamine alone causes a net bronchoconstriction
in man.

Normal subjects receiving histamine have been

reported

(110)

to experience an increase in respiratory

system resistance and closing volume and a decrease in
vital capacity (VC),
second

(FEVa),

parameters

forced

expiratory volume in one

and the ratio of FEV i to VC.

suggest

These

both large and small airways con¬

striction due to histamine.
Chlorpheniramine clearly prevents histamineinduced bronchospasm in children (137)
(5°.

and adults

71. 99)•
Maconochie,

subjects,

8 mg.

et al.

(99)

found that in healthy

or oral or 5 or 10 mg.

of intravenous

chlorpheniramine generally prevented histamine-induced
bronchoconstriction,

as measured by FEV1.
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However, 400 mg.
mg.

or oral cimetidine or 100 or 200

of intravenous cimetidine blockade of H2 receptors

had no effect on bronchoconstriction in the subjects
studied

(99).

These findings indicate the primary and

perhaps sole involvement of Hi receptors in histamineinduced bronchospasm in healthy,
The authors offer (99),

human airways.

as an explanation for the

lack of effect of cimetidine,

the possibility that

cimetidine did not reach the H2 receptors in the lung
in sufficient concentrations to produce an effect.
However,

the doses of cimetidine used were adequate to

inhibit gastric acid secretion and histamine challenge
did

coincide with peak blood levels of cimetidine.
Eiser (59) was similarly not able to demonstrate

the presence of H2 histamine receptors in normal human
airways.

He found that H£ blockade with 200 mg.

of

intravenous cimetidine had no effect on histamine-induced
changes in airway specific conductance in the nine
subjects tested.
however,

20 mg.

of intravenous chlorpheniramine,

significantly shifted the histamine dose-response

curve to the right.

Eiser found no difference between

chlorpheniramine administration and the administration
of chlorpheniramine and

cimetidine together (59).

Cimetidine has received wide clinical use since
its development.

In the clinical setting,
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it does not

appear that cimetidine promotes asthmatic bronchospasm (14).
However, Frith,

et al.

(71)

on a study of ten asthmatics.

are preparing a report

The subjects were selected

on the basis of histories of episodic dyspnea as well as
documented reversible airflow destruction.

Subjects

received an increasing dose of inhaled histamine until
a 20$ drop in FEV i was reached.

On subsequent days,

the same protocol was followed,

except subjects were

pretreated with chlorpheniramine 8 mg.
600 mg.

or cimetidine

or both.

The findings show that Hi blockade significantly
increased the level of histamine necessary to produce
a 20$ drop in FEV1

(p=0.0001)(71)•

differ from placebo.
ficantly (p=0.04)

However,

Cimetidine did not

cimetidine did signi¬

reduce the effectiveness of chlor¬

pheniramine when the two drugs were given together.
These results indicate the presence of histamine Hi and
H2 receptors in asthmatic airways,

although the H2

effect does not seem to be very profound.
do not address the
in their findings.

influence

The authors

of drug-drug interactions

The dose of cimetidine used was

at least twice that required to reduce food-stimulated
gastric acid secretion by 50$.
Nathan,

et al.

eleven asthmatics.

(109)

achieved similar results in

Chlorpheniramine significantly
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raised

(p less than 0.002)

the level of histamine

required to cause a 20 percent drop in FEV1 ,

a 35 percent

decline in maximum expiratory flow at 50 percent below
vital

capacity,

conductance.

or a fifty percent decrease in airway

Cimetidine significantly decreased the

amount of histamine necessary to produce these results
(p less than 0.02).
receptors,

The authors conclude that H2

mediating bronchodilation,

exist in asthmatic

airways.
Pretreatment with aerosolized diphenhydramine in
adult asthmatics significantly blocked the effects of
inhaled histamine (28)

as measured by the amount of

histamine required to produce a 20$ drop in FEVi.

This

result lends further support to the theory that histamine
produces bronchoconstriction by direct action on Hi
receptor sites.
Although oral antihistamines are of little clinical
use in asthmatics,

clemastine,

an Hi antagonist, when

delivered directly to the bronchial tree by inhalation
(113).

caused bronchodilation in asthmatics.

Pulmonary

function parameters were FEVa and peak expiratory flow
rate (PEFR).

In addition,

the histamine-dose response

curve was significantly shifted to the right (112).
These findings wree comparable to the results achieved
by salbutamol,

a @2 receptor agonist.
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The results of

this study may be due to complete blockage of Hi receptors
in asthmatics,

thereby allowing endogenous histamine to

react specifically with the only unblocked receptors,
H2 receptors,

thereby mediating relaxation in addition

to the obvious
activity.

elimination of bronchoconstricting Hi

An interesting follow-up study would investi¬

gate whether cimetidine reverses the bronchodilatory
effects of inhaled clemastine.
Dunlop and Smith (57)
Platshon (89)

as well as Kaliner and

have provided i_n vitro evidence for the

presence of histamine receptors in human airways.
and Smith (57)
bronchus,

showed,

2-3 mm.

in diameter,

Hi receptor blockade,
relaxation.

This

in vitro,

Dunlop

in sensitized human

that in the presence of

histamine agonism led to broncho-

effect could be eliminated by H2

antagonism with metiamide.

Furthermore,

in human

bronchus caused to contract due to exposure to house
dust mite antigen (57).
caused decreased

Ha blockade with mepyramine

contraction while H2 blockade caused

increased bronchial contraction.
Kaliner and

Platshon (89)

demonstrated that

2-methyhistamine produced an increase in cyclic GMP,
with subsequent enhancement of mediator release (SRS-A).
H2 agonism with dimaprit in the human lung caused in¬
creased levels of cyclic AMP with subsequent decreased
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release of SRS-A.

This finding indicates that H2

agonism with substances such as dimaprit might be use¬
ful in the treatment of anaphylaxis.
Histamine's action in asthmatic airways to cause
bronchoconstriction is almost entirely via direct
stimulation of smooth muscle receptors

(29).

asthmatics receiving a dose of atropine,
tholytic drug,

a parasympa¬

at a dose strong enough to achieve

cholinergic blockade,

the histamine dose-response

curve was slightly shifted to the right (29,
Thus,

In

in asthmatics,

84,

137).

histamine does not act primarily

through cholinergic pathways.
Similarly,

the vagal-blocker SCK 1000 did not

prevent histamine-induced bronchospasm in asthmatics
(150)

although it did prevent methacholine-induced

bronchospasm.

Histamine does have some reflex vagal

nerve irritant receptor action,
minor effect (3.

135)*

although this is a

In large airways,

it is proposed

that histamine has more of a reflex vagal effect (8, 47)
while in small airways,

constriction is due to direct

histamine Hi antagonism.
As is the case in other species,
pig and sheep,

such as the guinea

the distribution and sensitivity of

histamine receptors may vary in different parts of the
respiratory system such as in central versus peripheral
-30-

airways.

This possibility makes _in vivo studies in man

more difficult than in vitro studies.

Methodologies

must deliver histamine to specific parts of the airway.
Pulmonary function tests must be used to measure constric¬
tion or dilation in the specific stimulated sections of
airway under investigation.

Thus,

one would not want

to only measure large airways constriction in a protocol
where histamine is delivered mostly to the respiratory
bronchioles.

Since large airways have a reflex vagal

contribution to histamine-induced bronchospasm (47)

this

provides another factor which makes analysis of the presence
of histamine receptors jjn vivo difficult.
Pulmonary Vascular Histamine Receptors
The most profound effect of histamine on airway
mechanics is by its direct interaction with smooth muscle
receptors.

However,

interaction of histamine with

pulmonary vascular receptors is also very important in
the regulation of respiration.

Studies with a variety of

results have been performed in a number of animal species.
In the guinea pig.

histamine agonism leads to

pulmonary vasoconstriction.

This effect is most pro¬

found in the pulmonary veins (34,
(64)

115)*

It is proposed

that histamine-induced pulmonary venospasm may

increase right atrial pressure and thereby contribute
to the formation of pulmonary edema.
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The pulmonary

vasoconstriction appears to be mediated by Hi receptors
in the guinea pig.

Burimamide potentiates this response

Mepyramine has a depressor action on pulmonary vascula¬
ture,

indicating the presence of H2 receptors which

mediate pulmonary vasodilation.

Some authors feel that

pulmonary vascular

increase

sistance,

dilation

may

airway

re¬

through mechanical obstruction.

The rat exhibits pulmonary vasoconstriction in
response to hypoxia.
amide (10)

This effect is blocked by meti-

indicating that H2 stimulation leads to

pulmonary vasoconstriction in the rat.

This is the

opposite effect to be observed in the cat (?9,

145)

where Hi agonism causes pulmonary constriction and H2
agonism mediates dilation of pulmonary vasculature.
Comparable results are available in the dog (74).
Okpako (116)

demonstrated that H2 agonism with 4-methyl-

histamine had 15 times the vasodepressor potency of
2-methylhistamine.

This vasodepression could be

abolished by burimamide.
Tucker, _et al.
dog (145,

146).

arrive at similar results in the

Measuring pulmonary vascular resistance

they found that Hi agonism led to an increase in resis¬
tance, while H2 agonism caused a fall in pulmonary
vascular resistance.

Antagonists had the expected

results of reversal of the effects of agonists.
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The

authors also found (146)

that H2 blockade would also

potentiate pulmonary vasoconstriction during hypoxia.
Okpako (116)

concludes that H2 receptor agonism may

lead to "pooling of blood" in the bronchial mucosa
with resultant mechanical obstruction of the airway.
The effect of histamine on pulmonary vessels seems
to vary with development in dogs (111).

One group of

authors found that while metiamide potentiated pulmonary
vasoconstriction in canine pups,

this

effect disap¬

peared after 15 days of life.
In the horse (77).
vasoconstriction.
effect,

histamine causes pulmonary

This appears to be mostly an Hi

although H2 agonism may also contribute to

vasoconstriction to a lesser degree.
ewe (152),

In the nonpregnant

histamine also mediates pulmonary artery

constriction which may be blocked equally well by Hi
or H2 antagonists

(benadryl and metiamide).
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THE ROLE OF HISTAMINE IN PATHOLOGIC PROCESSES
Histamine,

Inflammation,

and the Allergic Response

As early as 1910 (42, 43), Dale and Laidlaw
appreciated the similarities between the effects of
histamine and anaphylaxis.
swelling,

edema,

Bartosch at aJL.

These include redness,

and hypotension.
(11)

Twenty years later,

demonstrated the presence of

histamine in guinea pig lung during the antigen-antibody
reaction.
Sensitized human lung and skin mast cells and leuko¬
cytes will release histamine in vitro when challenged
with specific antigens (1?)-

I_n vivo,

sensitized humans

and asthmatics experience increased plasma histamine
levels following allergen-induced bronchoprovocation
(17,

28).

The increase in histamine levels correlates

well with the onset of bronchospasm.
The release is initiated by IgE antibody bound to
the cell surface.

IgE-induced

effects are mediated by

alterations in cyclic nucleotides.
The fact that a second messenger,
the cyclic nucleotides cAMP and cGMP,

in this instance,
may act as the final

common mediators for the elaboration of the different
physiological responses of different tissues to antigenantibody interaction, may have been first proposed in
1919 (43)s
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So that it is quite possible that
the production by histamine, and by
a whole group of other substances,
of a complex including contraction
of plain muscle with relaxation and
permeability of capillaries, may
depend on a common type of physical
change in protoplasm produced by all
of them, the result of which receives
different expression in terms of the
physiology of different tissues.
Mechanisms of Histamine Interaction
In cells undergoing the IgE mediated antigenantibody reaction (Type I immediate hypersensitivity
reaction),

histamine,

acting on Hi receptors,

parti¬

cipates in an exquisitely fine-tuned mechanism to
promote the inflammatory process.

In addition,

hist¬

amine also acts on H2 receptors to provide a negative
feedback on its own actions
Step #1;

(3^)-

Histamine Release

Following the interaction of cell surface-bound
IgE antibody with specific antigen,
flux of extracellular calcium,

there is an in¬

important for the ini¬

tiation of release of histamine-containing granules.
This is followed by the energy-dependent activation of
microtubules and microfilaments which results in the
fusion of the perigranular membrane with the cell
membrane,

followed by exocytosis of granules.

Extra¬

cellular ions such as sodium then penetrate into the
granules with the resultant release of the histamine-
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heparin-protein complex by ion exchange (114).
Further release of histamine is modulated by intra¬
cellular levels of cyclic AMP and
will be seen,

cyclic GMP, which,

as

are themselves regulated by histamine.

Platshon and Kaliner (12*0

found that cGMP and cAMP

levels increased profoundly,

simultaneously with the

appearance of mediators in sensitized human bronchus.
Hi Receptors Promote the Inflammatory Response
Acting on Hi receptors,

histamine's effect on

smooth muscle is to facilitate contraction by in¬
creasing calcium entry.

This leads to depolarization

and impulse-carrying currents.
The sudden contraction, which is a result of
histamine release,

is followed by a brief period of

partial relaxation during the anaphylactic response.
This is followed by a secondary,

sustained contraction,

which is resistant to classical antihistamines and
which is attributed to the delayed release of non-hist¬
amine mediators such as SRS-A ( 38),
Cyclic GMP may be implicated in this Hi mediated
contraction.

Increased levels of cyclic GMP are found

following stimulation with histamine (124).

This

increase may be blocked by Hi antihistamines (124).
The rise in cyclic GMP is calcium-dependent (14).

The

role of cyclic GMP may be to activate protein kinases

-36-

which in turn enhance phosphorylation of proteins which
participate in calcium ion mobilization (14)

which in

turn leads to smooth muscle contraction.
Histamine seems to promote its own release through
Hi-mediated positive feedback (14).

Hi receptor anti¬

histamines inhibit the IgE induced release of histamine
as well as antigen-induced release of histamine from
sensitized monkey lung (14).
Hi receptor agonism enhances eosinophil migration.
Histamine causes release of prostaglandins from
the lung.

Indomethacin,

a prostaglandin synthetase

inhibitor,

diminishes allergic bronchospasm by 40^,

indicating a role of prostaglandins in allergic bronchoconstriction,

although the prostaglandin synthesis

which accompanies anaphylaxis has been considered
secondary to the action of histamine.

Suppression of

prostaglandin synthesis does not prevent hypersensitivityassociated rises in cAMP and cGMP.
The cyclic GMP dependent release of PGF 2CX and
thromboxane A2, which intensify bronchoconstriction,
may be inhibited by Ha receptor antagonism with pyrilamine or mepyramine

(64,

125).

Hi agonism with

2-methylhistamine promotes release of PGF 2CL and throm¬
boxane A2

(16,

124).

Histamine agonism of Hi receptors
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(and to a

lesser extent H2 receptors)
permeability.

also increases vascular

This facilitates the migration of immuno¬

globulins and leukocytes to the site of inflammation.
Hg Receptors Inhibit the Inflammatory Response:
Potentiation of Anaphylaxis By H2 Receptor Blockade
Histamine acts through H2 receptors in a different
manner than Hx receptors.

Stimulation of histamine

H2 receptors causes a rise in cyclic AMP (124).

Blockade

of the H2 receptor prevents a rise in cyclic AMP (2,
124,

134,

138),

except in mice, where Hx and not H2

receptor blockade prevents histamine-induced cAMP
accumulation (118).
Cyclic AMP facilitates calcium sequestration and
extracellular transport, with resultant relaxation of
contractile proteins.

Elevated levels of cyclic AMP

correlate with bronchial smooth muscle relaxation
and bronchodilation.
Effect on Histamine Release
H2 receptor agonism and the subsequent rise in
cyclic AMP is also very important in the regulation
of the immune process.

Elevated levels of cyclic AMP

inhibit histamine and and SRS-A release from the mast
cell and human leukocytes (21).
In humans allergic to ragweed,
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histamine is re-

leased upon exposure to ragweed antigen.
these human donors,

in vitro,

may be inhibited by histamine,
xanthines.

this release of histamine
isoproteronol,

or methyl-

Each of these substances acts to increase

levels of cyclic AMP (21).
(94)

In leukocytes of

Lichtenstein and Gillespie

demonstrated that H2 antagonists could prevent the

inhibition of histamine release from blood basophils.
Hi antagonists did not block this response.
Ovalbumin antigen caused dose-related release of
histamine from In vitro guinea pig lung.
Vickers

(56)

Dulabh and

found that H2 antagonism with cimetidine

or burimamide potentiated this release.

This demonstrates

the role of H2 receptors in modulating the immune responsemediated release of histamine.
In addition, metiamide or cimetidine potentiated the
antigen-induced bronchoconstriction in guinea pig lung
Other investigators have achieved similar results

(2,

(56).
90).

It appears that metiamide also potentiates the
antigen-induced release of histamine in sensitized rhesus
monkey lung (30,

31).

monkey skin (30)

in vivo.

Kaliner (124)

canine lung, bovine lung,
However,

and

Platshon and

were unable to prove that H2 blockade

potentiated histamine release in the human lung i_n vitro ■
H2 antagonism does not potentiate histamine release
from passively sensitized rat lung (30,
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34).

This

suggests that H2 agonism may not inhibit endogenous
histamine release in the rat (30)*
(80)

Holyroyde and Eyre

showed that H2 blockade actually prevented hist¬

amine release in sensitized bovine lung.

It is inter¬

esting to note that H2 blockade does not,

in some ex¬

perimental models

(30,

33.

88)

also enhance SRS-A

release from sensitized tissues.
result,

This is a curious

since SRS-A release is inhibited by increased

levels of cyclic AMP and H2 agonism increases cyclic
AMP levels.
Effect on Histamine Production, Metabolism,
Uptake, Storage, and Clearance
Not only does H2 agonism prevent release of
histamine,

it also inhibits production of histamine.

H2 antagonists induce histidine decarboxylase to pro¬
duce histamine

(10k,

125)*

Histamine metabolism is

also promoted by H2 receptor agonism and is inhibited
by H2 antihistamines (67,
was unable to show,

107,

however,

histamine mepyramine,

125)-

Taylor

(lkk)

that either the Hi anti¬

or the H2 antihistamine burima-

mide had any effect on histamine methyltransferase,
the enzyme which is involved in the methylation of
histamine,

the predominant mode of inactivation of

the mediator.

Blockage of the H2 receptor also

inhibits histamine storage in mast cells
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(l4,

107).

H2 antagonists prevent histamine uptake (3^.

68,

107)

and delay clearance of histamine from the circulation
(3^.

133)•

Effect on Other Participants in the Immune Response
Increased levels of cyclic AMP,
H2 agonism,
126).

the result of

also inhibit T-cell induced

cytolysis (14,

H2 agonists in high concentrations will inhibit

eosinophil migration (14)

as well as inhibit lysosomal

enzyme release from human polymorphonuclear cells
125).

Acting through the H2 receptor,

(93.

histamine will

inhibit the production of lymphokines.
Just as histamine acts upon Ha receptors to promote
PGF2a release,

histamine acts upon K2 receptors to

promote release of PGE,
cyclic-AMP-mediated,

a prostaglandin which has

bronchodilating activity.

PGE

may in turn inhibit further histamine release by acti¬
vation of cAMP in mast cells (16).

Metiamide can

antagonize histamine-induced release of PGE.
In conclusion,

histamine released during a hyper¬

sensitivity reaction may participate in a number of
mechanisms to provide feedback inhibition in order to
limit the severity of the reaction.

_4l _

Histamine, Antihistamines, and the Immune
Reaction in the Clinical Setting
Antihistamines as Preventors of the Inflammatory Response
Although histamine is a major mediator of anaphylaxis,
antihistamines have not been effective in the complete
control of this process.

Several reasons for this have been

suggested.

Other mediators are involved in the anaphylactic

response.

These include SRS-A,

and serotonin.

kinins,

prostaglandins,

SRS-A has been shown to be the mediator

responsible for the late,

prolonged phase of broncho-

constriction in the antigen-challenged human bronchus
(125).

Although H2 receptors seem to be most important

in inhibition of the inflammatory response,

to the effect

that they cause increased vascular permeability,
contribute to the inflammatory process.

they

Classical Ha

antihistamines have no effect on the H2 receptor contri¬
bution to this process.
Antihistamines nevertheless do have important
clinical relevance in the modification of the inflam¬
matory reaction.

Plaut (125)

found that cutaneous

reactivity to compound US/80 could be inhibited by
combinations of Hi antihistamines and cimetidine.
He proposes that H2 and H2 receptor blockade might be
helpful for treating some cutaneous manifestations of
allergic diseases such as chronic urticaria (125).

42

-

-

Similarly,

Harvey and Schocket (?8)

found that H2

antihistamines potentiated the effect of Hi antihist¬
amines in blocking the cutaneous wheal response,
although H2 antihistamines alone had no effect.
is suggested

(78)

that H2 receptors are somewhat in¬

volved in the cutaneous histamine response.
and Little (75)

Goadby

found that metiamide protected against

anaphylaxis in the guinea pig,
unusual,

It

a finding which is

considering the purported role of H2 receptors

in modifying the immune response.
Rocklin (129)

noted that in sensitized guinea pigs,

histamine in concentrations of 10-3M reduced the size
of a delayed hypersensitivity skin test.
could be reversed by an H2 antagonist.

This effect
He proposed

that histamine suppresses cutaneous delayed hyper¬
sensitivity in part,

by inhibiting the production and

proliferation of migration inhibiting factor (MIF).
H2 antagonists reversed this inhibition of MIF (129).
In so doing,

H2 antagonists such as cimetidine have

been shown to be of therapeutic value in allowing the
expression of cutaneous cell-mediated immunity.
example,

For

cimetidine is useful in the treatment of

selected deficiencies in the immunologic response to
Candida antigen (86).
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Antihistamines as Potentiators
of the Inflammatory Response
H2 antihistamines, by antagozing H2-mediated inhibi¬
tion of inflammation, may potentiate anaphylaxis.
and Smith demonstrated (57)

Dunlop

that metiamide potentiates

anaphylactic bronchoconstriction _in vitro .
the observation of Drazen, _et al.

(55)

This was

v*ho found that

H2 antihistamines burimamide and metiamide increased
the severity of immune-initiated anaphylaxis in the
guinea pig.

4-methylhistamine decreased the severity

of the reaction (55)dine,

Of note is the fact that cimeti-

another class of H2 antagonist,
Wolfe,

et al.

(151)

regarding cimetidine.

had no effect.

came to the same conclusion

They were unable to demonstrate

a prominent modulating role for H2 receptors in immediate
or delayed skin test reactivity.
(90)

Krell and Chakrin

were unable to find that H2 blockade with metiamide

potentiated antigen-induced or histamine-induced

changes

in dynamic lung compliance or pulmonary resistance in
the dog at doses up to 16 times the ED^q for inhibition
of gastric acid secretion.
as the sensitized
asthma,

They conclude that insofar

canine might be a model for human

it appears that H2 antihistamines may not be

deleterious to allergic asthmatics
While in one study,

(90).

cimetidine potentiated the
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anaphylactic response in the guinea pig (56),
doses were 100 micromoles per kilogram,

required

a dose between

50 and 100 times that required to inhibit maximal gastric
output by 50^ in the rat and dog (14).
that the results of Dulabh and Vickers

It is unlikely
(56)

can be ex¬

tended to conclude that a potential effect of thera¬
peutic doses of H2 receptor antihistamines would be to
cause intensified allergic reactions in man.
However,

a recent case report in the New England

Journal of Medicine (48),

described the appearance

of a hypersensitivity reaction which coincided with
the oral administration of cimetidine.

The reaction

disappeared after discontinuance of the H2 antagonist.
This finding was supported by the work of Avella,
et al.

(9)

who found that in patients receiving cimet¬

idine,

there was a significant enhancement of the

delayed hypersensitivity response to four common
antigens as

compared to controls.

This is most likely

due to the antagonism of H2 receptor mediated stimu¬
lation of suppressor T cell function (9).
Expecting that H2 blockade would remove inhibition
of the delayed hypersensitivity reaction, Dale (44)
noted that metiamide did not exacerbate the tuberculin
reaction in the guinea pig.

She concluded that other

factors in addition to histamine must regulate the

-4 5-

immune response.
The Role of Histamine in Asthma
Introduction
Asthma may be defined as a disease process
characterized by an increased reactivity of the
trachea and bronchi to various stimuli

(*0 .

leads to reversible narrowing of airways.
marked by increased

This
Asthma is

contraction of bronchial smooth

muscle and increased secretion of mucous in the bronchial
tree.

Asthma is manifested by the symptoms and signs

of dyspnea,

wheezing,

cough,

prolonged

expiration,

and responsiveness to bronchodilator drugs.
Asthmatic airways display hyperreactivity to a
number of stimuli.

These include specific allergens

such as house dust,

animal dander,

(114).

pollen,

and drugs

Other stimuli include suggestion (81,

97.

131»

l4o) , smoke, excercise (136), respiratory infections
(4), and emotional reactions (4).
The mechanism for the allergic hyperreactivity in
asthmatics is via the Type I immediate hypersensitivity
reaction which is mediated by the IgE antibody which
reacts with surface bound antigen.

Asthmatic broncho-

spasm is also mediated via Type III

hypersensitivity,

a late,

gradually appearing immune-complex reaction.
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The most important mediators of asthmatic bronchospasm are histamine and SRS-A.

Other mediators such

as bradykinin and prostaglandins play a less important
role.

Bronchoconstriction is mediated by chemical

mediators,

as previously discussed, via a rise in intra¬

cellular levels of cyclic GMP.

This in turn causes a

rise in intracellular Ca++ levels with subsequent
activation of contractile proteins.
In addition to chemical mediators,

bronchoconstric-

tion is promoted by increased parasympathetic tone.
Cholinergic stimulation similarly causes a rise in
intracellular calcium ion levels (Ilk).

Interaction

of bronchoconstricting elements with "irritant recep¬
tors"

causes reflex bronchoconstriction through vagal

stimulation.

Vagally-induced bronchoconstriction can

not be inhibited by classical Hi antihistamines,

although

it can be prevented by treatment with parasympathetic
blocking agents such as atropine or ipratropium bro¬
mide (11^-0.
Agonism with 3 2 receptors on respiratory smooth
muscle causes bronchorelaxation.

Neurotransmitters

which combine with 32 receptors will relax bronchial
smooth muscle.

The mechanism of bronchorelaxation

is via stimulation of cyclic AMP which causes decreased
calcium ion levels.

This increase in cyclic AMP

-k?-

which results from catecholamine stimulation,

also

decreases the antigen-induced release of histamine in
sensitized lung _in vitro (106).
Asthmatics may experience disturbances in any of
several mechanisms which lead to increased bronchial
activity.

They may display hypersensitivity to antigens,

increased responsiveness to histamine,
parasympathetic tone,
receptor)

abnormally active

or diminished sympathetic (3 2

responsiveness (106,

110,

142).

The following

pages will focus on the role of histamine in asthma.
The Role of Histamine in Asthma
The findings that histamine causes bronchoconstriction and is released in immediate hypersensitivity reac¬
tions have led to a strong association of asthmatic
bronchospasm with histamine (117).
histamine,

With regard to

asthmatics may experience an increased release

of histamine in response to bronchoconstricting stimuli
as compared to healthy humans.
For example,

in addition to the role of vagal

stimulation in exercise-induced bronchospasm,
also seems to be involved.

Simon,

that among some asthmatics,

excercise provoked a fall

in pulmonary function (FEVi).

et al.

histamine
found

This decline in FEV a

correlated well with increased levels
the peripheral venous blood.
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of histamine in

Asthmatics may also have an increased sensitivity
to the histamine which is released.

Indeed,

asthmatics

develop bronchoconstriction in response to lower concen¬
trations of inhaled histamine than do normal persons
(91,

110,

139).

This fact is useful in the identifi¬

cation of persons with hyperreactive airways

(109).

There is some evidence in the mouse model for asthma,
that histamine sensitivity may be in part,
table trait

an inheri¬

(l4?).

In addition,

asthmatics differ from normals in

that asthmatics have detectable levels of histamine
in their plasma

(17)

even without antigen challenge.

Nonasthmatics do not have any detectable level of
endogenous histamine in their plasma.
Asthmatics might suffer from an imbalance in the
numbers of different types of histamine receptors
which have opposing effects on bronchial smooth muscle.
This theory is supported by recent experimental evidence.
Busse and Sosman (26)

noted that histamine,

through H2 receptors,

inhibits serum-activated

induced lysosomal

acting
zymosan-

enzyme release from granulocytes.

This response parallels a simultaneous increase in
levels of cyclic AMP.

The authors found

this Hs-mediated inhibition of lysosomal

(26)

that

enzyme release

is significantly decreased in asthmatics as well as
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normal volunteers infected with rhinovirus l6 (24).
This suggests that asthmatics have decreased numbers
or sensitivity of H2 receptors.

Furthermore, viruses

may exacerbate the asthmatic condition through their
effect on H2 activity.
The decreased responsiveness of H2 receptors in
asthmatics is important.

The antigen-antibody reaction

might initiate a selective increase in cyclic GMP level
in asthmatics

(124).

Since the H2 receptor acts to

control further histamine release from sensitized

cells

as well as acts to stimulate histamine metabolism and
uptake,

diminished H2 reactivity would

levels of endogenous histamine.

cause increased

In asthmatics,

who

are sensitive to even minute quantities of histamine,
this increase in histamine levels would lead to further
bronchoconstriction.

For the same reason,

H2 blockade

in asthmatics would be expected to be more deleterious
than in non-asthmatics, because the slight increases
in histamine would

effect asthmatics,

whose Hi receptor

are much more sensitive to slight increases in the
levels of histamine.
Airway obstruction in asthma is due,
to inflammatory changes in the bronchi.

in part,
Granulocytes

may be found in the respiratory tree in increased
numbers during bronchial reactivity.
-50-

Important medi-

ators of this inflammatory response are the lysosomal
enzymes.

Decreased inhibition by the H2 receptor of

these lysosomal enzymes may contribute to the inflam¬
matory response in asthmatics

(26).

It is interesting

to note that persons with other defects in immune re¬
sponsiveness,

such as those with atopic eczema,

may

also have diminished H2 receptor-mediated inhibition
of the inflammatory process
Some authors,

however,

(25).
have found no difference

between H2 receptor responsiveness in asthmatics and
non-asthmatics.

Gillespie et al.

(73)

found no signi¬

ficant difference between asthmatics and non-asthmatics
in the effect of histamine on lymphocyte cAMP levels
(an H2 receptor-mediated process).
The finding that asthmatics have decreased H2
receptor responsiveness is analagous to the decreased
responsiveness of 32 adrenergic receptors seen in
asthmatics as compared

to non-asthmatics
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(106, 110, 142).

HISTAMINE RECEPTORS IN THE AIRWAYS OF
HEALTHY, HUMAN SUBJECTS
Introduction
While many of the previously described studies
have provided

excellent evidence for the presence of

histamine Hi and H2 receptors in the airways
species,

of manv

there is little evidence for the presence

of H2 receptors in human airways.

Should H2 receptors

exist in normal or asthmatic airways,
provide a role in bronchodilation,

and should they

as in animal models,

this finding might have important therapetic implica¬
tions.

For example,

H2 receptor agonists might be

useful as bronchodilators.

Furthermore,

caution might

need to be followed in using H2 receptor antagonists
in persons with compromised respiratory function.
Evidence to date includes i_n vitro studies on the
presence of H2 receptors in sensitized human bronchus
(57.

89).

Two recent studies in non-asthmatics

(59.

99)

have found no evidence for the presence of H2 receptors
in the airways of non-asthmatics.
(71,

109)

Two recent studies

provide preliminary evidence that Hi and H2

receptors are present in asthmatic airways,

and H2

receptors mediate bronchodilation.
The following experiment describes an investigation
of the effects of histamine Hi and H2 receptor blockade
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in the airways of healthy,

non-asthmatic,

human subjects.

The goal of the experiment was to provide evidence for
the presence or absence of Hx and H2 receptors in the
small airways of normal man.
Materials and Methods
Subject Selection
Subjects were recruited as paid volunteers.
gave written,

informed

the experiment,

They

cinsent for participation in

as approved bv the Yale University

School of Medicine Human Investigations Committee.
Eleven healthy,

non-asthmatic subjects

3 females)

ranged in age from 18 to 35-

was 26.3 -

5-1 years.

(8 males,

The mean age

All had no history of asthma

or recent respiratory diseases which could
an asthmatic response to histamine

(26,

simulate

6c).

Baseline

pulmonary functions were at least 85^ of normal predicted
values for the group as a whole.

(TABLE I)

Histamine preparation
Histamine dihydrochloride

(Sigma,

St.

Louis) was prepared

in normal saline as a stock solution of 128 mg.
ml..

base

Stock solution was kept frozen when not in use.

Serial dilutions of the stock solution provided
concentrations of histamine used for the study.
jects received histamine challenges of 0.1,
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2, 6,

Sub¬
8,

16 .

32 ,

64,

and 128 mg. /ml.

(9x 10‘4M to 1.15M; pH=? .0 to 3.7).

Drugs Used
All drugs were administered single-blindedly.
Cimetidine 300 mg.

(Smith, Kline,

and French,

is a highly specific H2 receptor antagonist

Philadelphia)

(22).

It was

selected because of its recent wide use in the treatment
of various illnesses,
disorders

(149).

particularly gastrointestinal

The dosage of the drug provided a

blood level of cimetidine of twice that required to
suppress by 80^,

secretion of gastric acid by the

stomach (149).
Chlorpheniramine maleate 8 mg.

(USV,

Tuckahoe),

an alkylamine derivative, was selected because of its
negligible sedative and anticholinergic effects as well
as its high specificity for Hi receptors as compared
to other Hi antihistamines

(119)•

A lactose placebo dispensed in a pink gelatin cap¬
sule

(Eli Lilly and Company,

Indianapolis)

Medications were administered orally,
night fast,

was used.
after an over¬

li to 2 hours prior to histamine challenge,

a

time designed to coincide with peak levels of each drug
(127,

130,

iramine,
149)

149).

No side effects of cimetidine,

or placebo were reported.

chlorphen¬

Since both cimetidine (143,

and chlorpheniramine (122) have very short physiological

and pharmacological half-lives,
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the possibility of

drug-drug interactions was negligible,

since the drugs

were administered at least 24 hours apart.
Aerosol Challenge
Histamine was delivered via a Dautrebande D-30
nebulizer

(45,

46),

driven by 20 pounds per square

inch of compressed air (0.5 ml.
Particles

liquid nebulized/min.).

of histamine were thus consistently aerosol¬

ized to less than 0.5 microns in diameter.

This assured

deposition of histamine in the respiratory bronchioles
and lung alveolar spaces.
Subjects wore a noseclip and inhaled the histamine
through a mouthpiece attached to a separate, valved
breathing circuit.

Histamine was inhaled for 3° seconds

by tidal breathing.
the effects

Tidal breathing controlled against

of deep inspiration on pulmonary function

in non-asthmatics

(108).

Adverse symptoms to inhaled

histamine at highest challenge doses included headache,
cough,

flushing of the skin,

tightness.

tachycardia,

and chest

Higher doses of histamine were not given

to subjects after the onset of adverse symptoms.
Pulmonary Function Testing
Histamine induces large airway constriction
through both direct agonism with Hi receptors,
a lesser extent, by vagal mechanisms.
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and to

Peripheral

airway constriction is almost entirely the result of
direct agonism with Hi receptors of smooth muscle
(8,

47).

Keeping in mind the fact that histamine was

being delivered primarily to small airways, the pulmonary function
tests selected for this experiment were selected for
their sensitivity in measuring small airway constriction.
A particularly sensitive measure of small airways con¬
striction is the MEF40(P),

the maximum expiratory flow

at 60 percent below vital capacity on a partial expira¬
tory curve

(20,

105).

This test measures flow during

the part of expiration which is independent of expira¬
tory effort.

The flow at 60 percent of vital capacity

is determined by the static recoil pressure of the lung
and the flow-resistive properties of small airways
(20,

105).
The particular sensitivity of the partial flow-

volume curve may reflect the absence of the effects
of a deep inspiration required for the generation of
maximal expiratory flow volume curves

(69.

72,

108).

All subjects were familiarized with the breathing
maneuvers and

equipment at the beginning of the study.

Breathing maneuvers were repeated until reproducible
curves could be obtained.
Subjects blew into a cardboard tube attached to
a computerized pneumotachograph-integrator system (148)
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which calculated flow and volume.

The measurements

were recorded on a Gould x-y recorder (slew rate of
40 inches per second).

The equipment was calibrated

daily.
Subjects expired to residual volume,

then inspired

to approximately 50-70% of their vital capacity.
wearing a noseclip,

While

the subjects then expired into the

cardboard tube as fast as possible to residual volume,
thereby generating the partial expiratory flow-volume
( PEFV)

curve.

Next,

subjects inspired to vital

capacity and then

expired as fast as possible to residual volume,

thereby

generating the maximal expiratory flow-volume (MEFV)
curve.

A programmable marker,

second,

permitted identification of the forced expira¬

tory volume at 1

second

set to trigger at 1

(FEVi).

The resultant curves

allowed measurement of the forced vital capacity (FVC),
peak expiratory flow rate (PEFR),

and maximum expira¬

tory flow rate at 60% below vital capacity on the MEFV
curve (MEF40)

and

PEFV curve (MEF40(P)).

(Figure 1)

FEVX is a particularly sensitive measure of airway
obstruction during a relatively effort-independent
portion of the curve.
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Protocol
Each day of the experiment,

there were controls

against factors known to influence responses to hista¬
mine

(87)-

Each day,

pre-challenge flow-volume maneuvers

were performed to establish the baseline for the day.
The baseline FEVa and MEF40(P)
day was

for the subjects on each

expressed as a percent of the baseline on Day 1.

(TABLE II)

Histamine challenge was performed at the

same time of day to control for diurnal variations in
histamine response

(49,

95)-

Day _!--Histamine Dose Response
On Day 1,
determined.

the baseline pulmonary function was

Prior to each histamine challenge,

each

subject repeated three flow-volume maneuvers to estab¬
lish a pre-challenge control value.
doses of 0.1 mg./ml.

of histamine,

Starting with
subjects received

a histamine challenge as previously described.

Inhala¬

tion of histamine was followed immediately by pulmonary
function testing at 0,

1,

2,

4,

6,

and 8 minutes.

The

averages of the first three and second three blows
were calculated.
If a subject did not experience a 20% fall
MEF40 (P)

in

as compared to pre-challenge control values,

within the first three minutes,

then the next successive

dose of histamine was administered after a thirty-minute
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wait.

The wait between successive doses of histamine

challenge was designed to control against any cumula¬
tive effect of histamine (8?).

Pre-challenge controls

expressed as a percentage of the baseline for Day 1
are recorded in TABLE III.
When a subject experienced a 2C% decline in
MEF40(P)

as compared to pre-challenge control,

dosage was referred to as the "threshold"

this

dose.

(Figure 2)
Days 2, J,

and 4--Premedication With Antihistamines

On each of Days 2,

3>

and 4,

subjects were given,

on successive days,

an oral dose of Hi antihistamine

(chlorpheniramine),

H2 antihistamine (cimetidine),

or placebo (lactose) ,

if- to 2 hours prior to histamine

challenge.
Baseline pulmonary function was determined at the
beginning of each day.

Prior to each histamine challenge,

each subject established a pre-challenge control value
as on Day 1.

Pre-challenge controls as a percent of

baseline for Days 2,

3>

and 4 are recorded in TABLE IV.

Each subject received a dose of histamine at one
dose below the threshold dose as determined
(T-l).

on Day 1

Subjects also received a histamine challenge

at threshold dose

(T)

and one dose above the threshold
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(T+l).

Each histamine challenge was followed by

pulmonary function testing at 0,

1,

8 minutes after histamine challenge.

2,

4,

6,

and

The averages of

the first three and second three blows were calculated
for MEF40(P)

and FEV i.

The average of the first three

blows was calculated as a percentage of the pre-challenge
control.(TABLE V)(Figures 3 and 4)
Analysis of Data
The means and standard deviations for the pulmonary
function tests were calculated.

Using this information,

a t-test for the comparison of two means

(58)

was used

to compare changes in daily baseline or pre-challenge
control pulmonary function,

as well as changes in

pulmonary function following histamine challenge as
compared to pre-challenge control values.
Underlying the comparison of the MEF40(P)

values,

is the assumption that the air flow reflected a defined
lung volume.

This

could be the case only if total lung

capacity remained unchanged during histamine provocation.
Total lung capacity has indeed been shown

(20,

l4l)

to

remain constant during induced bronchoconstriction in
asthmatics and normal subjects.
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Results
Analysis of the baseline FEVi and MEF40(P)
each day (TABLE II)

for

shows that pulmonary function did

not significantly vary from day to day.
A clear dose response curve (TABLE VI)
generated for histamine inhalation.

could be

The effects of

histamine on pulmonary function for the group became
significant at 32 mg./ml.

for both the MEF40(P)

FEVi curves.

The MEF40(P)

than the FEV1

curve at doses of 32 mg./ml.

ml. . (Figure 2,

and

curve was more significant
and 64 mg./

TABLE VII)

There was a slight cumulative effect of histamine
on pre-challenge control levels at 64 mg./ml.
mine.

of hista¬

(TABLE III)
Chlorpheniramine significantly prevented the decline

in MEF40(P),
to Day 1.

at threshold doses of histamine,

as compared

Pulmonary function values for placebo and

cimetidine were not significantly different at threshold
as compared to Day 1.

(TABLE VIII)

Pretreatment with chlorpheniramine significantly
protected against the fall in MEF40(P)
placebo at doses

(T)

and

(T+l).

as compared to

Significant protection

of chlorpheniramine against the fall in FEV1 as compared
to placebo was apparent at dose (T+l).

There was no

significant difference between placebo and cimetidine
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for either MEF40(P)
histamine.

or FEVi at any test dose of

(Figures 3 and 4,

TABLES V,

VIII,

and IX)

Discussion
Various conclusions may be drawn from this study.
It can be seen from the comparison of baseline pulmonary
function from each day that chlorpheniramine,

cimetidine,

and placebo each had no bronchoconstrictory or bronchodilatory effects on baseline pulmonary function.
(127)

Popa

studied the effects of oral and intravenous chlor¬

pheniramine in asthmatics.

He found that chlorphenir¬

amine did improve baseline pulmonary function.

However,

this study examined the effect of chlorpheniramine on
non-asthmatics.

The difference in findings may be due

to the relative absence of endogenous histamine in non¬
asthmatics as compared to asthmatics

(1?)

in addition

to the decreased sensitivity of non-asthmatics to the
little endogenous histamine which may exist
139).

Thus,

(91.

110,

while chlorpheniramine may block Hi recep¬

tors in asthmatics which would otherwise be stimulated
by histamine,

chlorpheniramine blocks receptors in

non-asthmatics, which,

in the absence of exogenous

histamine provocation, would otherwise not be agonized.
Subjects could not be excluded from the study if
baseline pulmonary function varied from day to day,
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as

this variation might be attributed to the effect of
the drug.

Exclusion of these persons might therefore

skew the results in favor of persons in whom the drugs
had no effect.
The finding that baseline pulmonary function did not signifi¬
cantly vary daily added,
the study.

Benson

(15)

in retrospect,

a useful control to

found that the resting state

of the airways was an important determinant of bronchial
reactivity.
dine,

Thus,

if either chlorpheniramine,

cimeti-

or placebo increased the resting bronchomotor

tone in the airways,

they could have potentiated subse¬

quent bronchoconstriction due to histamine.
It may also be concluded that one dose of 3°0 mg.
of oral cimetidine has no effect on baseline pulmonary
function in non-asthmatics.

It would be premature to

extend this conclusion to the clinical setting of
continuous cimetidine use in non-asthmatics.

However,

this finding suggests the possibility of conducting
such a study which would
non-asthmatics before,

examine pulmonary function in

during,

and after chronic

cimetidine use.
This study confirmed that the methodology used
can successfully generate a dose response curve for
inhaled histamine provocation.
ness of the MEF40(P)

Furthermore,

the useful¬

pulmonary function test as a
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sensitive measure of bronchoconstriction has been
demonstrated.

The measurement of MEF40(P)

is particularly

useful in measuring small airways constriction.

In

the Dautrebande D-30 nebulizer is particularly

addition,

useful in delivering small histamine particles to the
smallest airways.

It may thus be concluded that recep¬

tors mediating bronchoconstriction, which are stimulated
by histamine,

exist in the small airways

of healthy,

human subjects.
A small cumulative effect of histamine was observed
to occur on Day 1

as evidenced by pre-challenge pulmo¬

nary function, upon reaching a dose of 64 mg./ml.,

the

highest threshold dose of histamine for any subject.
However,
2,

3*

Day 1

no cumulative response was apparent on Days

and 4.

The finding of a cumulative response on

is surprising.

Juniper,

et al.

(8?)

found no

such response after waiting only five minutes between
successive histamine challenges,

although they did

not challenge anyone with more than 16 mg./ml.
histamine.

of

Perhaps the time required to adequately

clear 32 mg./ml.

from the respiratory system,

as

delivered to the airways by the protocol used in this
study is greater than the thirty minutes which was
permitted before the 64 mg./ml.

challenge.

The small

decline in baseline pulmonary function prior to the

-64-

64 mg./ml.

challenge might also be attributed to the

general fatigue of the subjects, who spent over two
hours waiting and who previously performed the pulmonary
function maneuveur more than for any other test dose.
Chlorpheniramine had a very significant effect
in preventing induced bronchoconstriction due to
histamine inhalation.

Blockade of the Hi receptors

with the oral medication was significantly greater than
placebo.

The difference between chlorpheniramine and

placebo could be detected at both the threshold and
superthreshold doses of histamine.
dose response curve, MEF40(p)

As in the histamine

Was a more sensitive test

than FEVi in detecting differences between chlorphenir¬
amine and placebo,

as well as detecting the protective

effect of chlorpheniramine as compared to the histamine
dose response curve.
Chlorpheniramine did not have a completely protective
effect against the bronchoconstricting effects of hista¬
mine.

This may have been due,

in part,

to incomplete

antagonism of all the Hi receptors in the small airway
by the oral medication.
such as clemastine

(113)

Inhaled Ha receptor antagonists,
have apparently been more

successful than oral medications in providing Ha
antagonism in asthmatics.

In fact,

clemastine (113)

causes bronchodilation in asthmatics,

-65-

perhaps by leaving

endogenous histamine free to stimulate bronchodilating H2
receptors.
Chlorpheniramine is a competitive antagonist of Hj
receptors.

Thus,

high concentrations of histamine,

those which may have been by the T+l

dose,

such as

could displace

the antagonist from the receptor.
A small component on the bronchoconstriction due to
histamine may have been the result of vagally-mediated,
bronchoconstriction (52).

Histamine particles,

reflex

particularly

those with a moderately acidic pH among the higher doses,
may have stimulated irritant receptors,
larger airways

(47)

to cause bronchoconstriction which can not

be prevented by Hi antagonism.
agents,

particularly in the

such as atropine,

In this study,

parasympatholytic

may have provided additional protection.

Unlike inhaled clemastine (113).

chlorpheniramine did

not yield any bronchodilation either at baseline or upon
histamine challenge.

This result does not support the

presence of H2 receptors in the normal human lung which
mediate bronchodilation.
The absence of an H2 receptor-mediated broncho¬
dilation at baseline may be explained as due to either
the absolute deficiency of H2 receptors,

or more likely,

the absence of endogenous histamine in non-asthmatics
which could bind with H2 receptors.

The fact that

histamine challenge did not yield bronchodilation

-66-

during Hi receptor blockade,
lack of H2 receptors.

It may also be possible,

with the oral medication,
of histamine,

may be due to the absolute
that

even at subthreshold levels

there were still an adequate number of

unbound Hi receptors agonized by histamine to counter
any effect of H2 agonism.

Thus,

a net bronchoconstric-

tion would be observed.
Further studies in the non-asthmatic might explore
the possible bronchodilatory effects of an inhaled
antihistamine on both baseline pulmonary function and
response to histamine challenge.

Smaller doses of

histamine than those which were used in this study
might simulate endogenous levels of histamine in the
asthmatic and agonize any possibly existent H2 receptors
without displacing Hi antagonists and

causing a net

Hi receptor-mediated bronchoconstriction.

Pretreatment

with an H2 antagonist in addition to an Hi antagonist
on the same day might remove H2-mediated bronchodilation,
resulting in a significantly larger net bronchoconstriction than in pretreatment with only an Hi antagonist.
No placebo effect was observed.

Placebos have

been reported to influence the amount of bronchoconstriction due to histamine provocation

(131).

However,

the placebo has to be presented to the subject as a
substance which has a bronchoconstricting or broncho-

-67-

dilating effect.

Subjects in this study were not

informed as to what the effects of the drugs might
be with regard to subsequent histamine challenge.
Cimetidine was no different than placebo with
regard to pulmonary finction observed upon histamine
challenge.

Blockade of H2 receptors neither protected

against or potentiated bronchoconstriction.

If H2

receptors, which mediated bronchoconstriction,
in the lung,

existed

then cimetidine would be expected to

have a protective effect,

as was the case with chlor¬

pheniramine .
If H2 receptors which mediate bronchorelaxation
were successfully anatagonized by cimetidine,

then

subsequent histamine challenge would stimulate only
Ha receptors.

This would promote an even greater

bronchospasm than that observed with placebo,

in which

case, both Hi and H2 receptors are stimulated.
The H2 receptor has been implicated,
AMP mechanisms,

through cyclic

to have a variety of effects which

would inhibit the effects of histamine challenge.
These effects include H2 receptor-mediated inhibition
of further histamine release (9*0.

inhibition of

histamine production

(104,

125).

metabolism (67.

125).

promotion of histamine

107,

promotion of histamine

clearance from the circulation (34,

68

-

-

133).

and promotion

of histamine uptake by mast cells
Blockade of these effects,
on metabolism,

uptake,

(3^ »

68,

107).

particularly the effects

and clearance,

by cimetidine

would also potentiate histamine-induced bronchospasm.
However,

cimetidine was not successful in potentiating

histamine-induced bronchospasm.
These findings are consistent with the preliminary
reports of Eiser (59)

and Maconochie (99) who also

found no bronchoconstrictory effects of cimetidine.
The most likely conclusion to be drawn from the evi¬
dence is that H2 receptors do not exist to any signi¬
ficant degree in non-asthmatic airways.
are present in the lung,

If H2 receptor

the effects of H2 agonism are

negligible compared to the bronchoconstrictory effects
of Hi agonism.
If there are few H2 receptors in the lung,

it is

possible that at the doses of histamine used for this
experiment,

the histamine overcame the competitive

antagonism by cimetidine for H2 receptor sites in the
lung.

Thus,

cimetidine might have been displaced from

the opportunity to potentiate bronchospasm.

At lower

levels of histamine agonism, H2 blockade might have
potentiated bronchospasm.

While it is difficult to

measure bronchospasm in non-asthmatics at low levels
of histamine challenge,

asthmatics are much more

69

-

-

sensitive to low levels of histamine (91.

110,

139).

The finding that cimetidine promotes bronchospasm in
asthmatics

(71,

109) may be due to the fact that

cimetidine is not displaced by the low levels of
histamine used in the histamine challenges.
tion,

In addi¬

acting through mechanisms which potentiate the

presence and release of histamine (34,

67,

68, 94,

104, 125. 133) small levels of additional histamine
which would not provoke bronchospasm in the non¬
asthmatic might potentiate bronchospasm in the sensi¬
tive asthmatic.
It is possible,
Macanochie,

et al.

as has been pointed

(99)

out by

that the cimetidine used in

this study did not achieve adequate levels in the
lung.

Cimetidine levels in human lung following oral

administration have not been studied.
cimetidine on histamine metabolism,
have also not been investigated.
of cimetidine used
level

The effects of

uptake and

However,

clearance

the dosage

in this study provided a blood

of twice that required to inhibit gastric acid

secretion in the stomach by 80%.
Perhaps future studies could investigate the effects
of an inhaled H2 agonist,

such as 4-methylhistamine or

dimaprit on pulmonary function.

Future studies could

also investigate the effects of an inhaled H2 antagonist,
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in hopes of achieving better penetration in the lung
than with oral administration.
A possible reason for the findings of this investi¬
gation may be the failure of cimetidine to adequately
antagonize the histamine receptors in the lung which
mediate bronchodilation.

A previous study (66)

demon¬

strated that cimetidine did not potentiate the depressor
actions of histamine in tissue in which burimamide and
metiamide, which belong to a different class of H2
antagonists,

potentiated the depressor effects on carotid

blood pressure.

Similarly,

a subclass

of H2 receptor

not antagonized by cimetidine, might be present in the
human lung.
Several other studies have demonstrated the
presence of histamine receptors in the airways of the
cat (35).

horse

(37,

39),

rat,

ferret (40),

(36,

70) which mediate bronchodilation and can be

agonized by 4-methylhistamine (40),

and rabbit

yet which cannot

be antagonized by conventional H2 antihistamines.
Perhaps such a class of H3

receptors may exist in human

lung.
Histamine was aerosolized so as to reach the smallest
airways

(45, 46).

The MEF40(P)

pulmonary function test

is particularly sensitive to small airways constriction
(20,

105).

If H2 receptors in the human lung exist
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predominantly in the large airways,

the protocol

of

this investigation may not have been sensitive enough
to document any effects

of H2 blockade.

Regional

differences in the distribution of H2 receptors has
been demonstrated in several animal species

156).

(14,

64,

For example, H2 histamine receptors are more

prominent in the central airways than the peripheral
airways in the guinea pig (156).
The regional differences in histamine receptor
distribution may correlate with the physiologic impor¬
tance of maintaining the patency of the large airways.
An alternative study could examine the effects of
larger aerosolized histamine particles
flow resistance,
tance (98),

on pulmonary

a sensitive measure of central resis¬

in order to more closely investigate the

presence of H2 receptors in large airways.

Atropine

would have to be used in this proposed protocol,
because of the relative importance of irritant receptors
in the large airways.
In conclusion,

the experimental evidence presented

in this investigation confirms the presence of Hi
receptors in the airways of healthy human subjects.
These receptors appear to mediate bronchoconstriction
and can be successfully antagonized by chlorpheniramine.
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The role of H2 receptors in healthy human airways,
as either bronchodilators acting directly on smooth
muscle or as inhibitors of the presence of histamine,
appears to be negligible under the conditions
protocol used in this study.

of the

Cimetidine did not potentiate

histamine-induced bronchospasm.

The role of H2 receptors

in asthmatic bronchoconstriction and bronchodilation
remains a possibility for future investigation.
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MAXIMAL

AND PARTIAL EXPIRATORY FLOW-VOLUME

VOLUME FROM TLC (liters)

Figure 1
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CURVES

HISTAMINE DOSE RESPONSE AS CHARACTERIZED
BY TWO MEASUREMENTS OF PULMONARY FUNCTION

Pulmonary Function
(% of pre-challenge control)

( FEV, and MEF AOl (P) )

Figure 2
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THE EFFECT OF ANTIHISTAMINES

MEF40(p,

(% of pre-challenge control )

ON HISTAMINE CHALLENGE AS MEASURED

Figure 3
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THE EFFECT OF ANTIHISTAMINES
ON HISTAMINE CHALLENGE AS MEASURED
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TABLE I
ANTHROPOMORPHIC DATA

FVC

FEV i

FEV 1%

PEFR

mef50%

Age

Mean

4.41

3.68

83-9

8.21

4.50

26.3

Standard
d eviation

0.82

0.69

9-3

1.62

2.10

5-1

Percent of
expected
values

89%

94%

93%

102%
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TABLE II

BASELINES AT BEGINNING OF DAY
AS PERCENTAGE OF BASELINE ON DAY 1

1

CM

CH

P

FEV i

100

99.6

99.8

99.0

mef40(p)

100

98.1

104.6

109-9

DAY

CM=Cimetidine
CT=Chlorpheniramine
P =Placebo
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TABLE III

AVERAGE HISTAMINE DOSE-RESPONSE
PRE-CHALLENGE CONTROLS AS
PERCENT OF INITIAL BASELINE

DOSE

.1

2

4

8

16

32

64

FEV 2

100

100

98.9

98.1

98.6

99.0

100.7

10c

110

94.1

102.4

98.1

93-9

89-0*

MEF4

(P)

*p= .031
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TABLE IV

PRE-CHALLENGE CONTROLS ON DAYS 2, 3, ANT) 4
AS PERCENT OF INITIAL BASELINE

CIMETIDINE
DOSE

T-l

T

T+l

FEVa

100

98.45

98.6

mef40(p)

10O

101 .4

101 .9

CHLORPHENIRAMINE
DOSE

T-l

T

FEVi

100

IOO.36

mef40(p)

100

102.3

T+l
100.8
98.4

PLACEBO
DOSE

T-l

FEV x

100

99.5

102.0

mef40(p)

100

97.0

95.4

T

T=Threshold Dose
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T+l

TABLE V
THE EFFECT OF PRETREATMENT WITH ANTIHISTAMINE
UPON SUBSEQUENT RESPONSE TO HISTAMINE
(Means * Standard Error of the Mean)

FEV2

DOSE

T-l

T

T+l

CIMETIDINE

99.0

93-64

86.0

±1.13

±2.79

±4.30

101 .72
±1 .71

98.91
±1.23

96.09
±2.60

101.88
±4.42

95-75
±2.54

85-88
±2.49

T-l

T

T+l

96.0
±4.26

79-64

57.80

±3.70

47.39

99.0
±4.17

91.45
±2.54

±5.58

91.88
±3.66

78.13
45.72

CHLORPHENIRAMINE

PLACEBO

MEF40(P)

DOSE
CIMETIDINE

CHLORPHENIRAMINE

PLACEBO
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82.18

57.88
45.15

TABLE VI

HISTAMINE DOSE RESPONSE
AS PERCENTAGE OF PRE-CHALLENGE CONTROL
(Means i Standard Error of the Mean)

DOSE

8

16

32

101 .1

103

98.63

101.6

99.45

91.0

12.65

10

±1-39

12.01

±0.73

13-59

99.90

97

100.5

94.2

92.0

79-72

73-29

12.68

lo

±3.1?

12.46

±3-90

14.92

14.53
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MEF40(

4

oo

FEV i

64

2

.1

12.98

TABLE VII

RESPONSE TO INHALED HISTAMINE
AS COMPARED TO RESPONSE TO
0.1 MG./ML. OF INHALED HISTAMINE

DOSE

4

8

16

32

64

FEV i

NS

NS

NS

p<.0 5

p<.0 5

mef40(p)

NS

NS

p= . 10

p<.005

p<.001

NS=No significance
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TABLE VIII

COMPARISON OF THE PROTECTIVE EFFECT
OF CHLORPHENIRAMINE, CIMETIDINE, AND PLACEBO
UPON SUBSEQUENT RESPONSE TO INHALED HISTAMINE
AS MEASURED BY MEF40(P)

DAY 1

CHLORPHENIRAMINE(CT)

CIMETIDINE(CM)

PLACEBO

DAY 1
T-l

■if-****

NS
p<.0025

T
T+l

NS

NS

NS

NS

*

*

NS

NS

CT
T-l
T
T+l

NS
p< .0025
*

■*■*•*■*•*

pc. 01

pc. 05

*■**■*•#■

p<.0005

p< .00 5

CM
T-l

NS

T

NS

p<.01

T+l

*

pc.0005

NS

NS
•a-#**-*

NS

P
T-l

NS

NS

NS

T

NS

pc.05

NS

T+l

*

pc.005

NS

♦Insufficient data to make comparison
NS=No significance
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TABLE IX

COMPARISON OF THE PROTECTIVE EFFECT
OF CHLORPHENIRAMINE, CIMETIDINE, AND PLACEBO
UPON SUBSEQUENT RESPONSE TO INHALED HISTAMINE
AS MEASURED BY FEV x

DAY 1

CHLORPHENIRAMINE(CT)

CIMETIDINE(CM)

PLACEBO(P)

DAY 1
T-l

P=.0 7

NS

NS

T

p=. 14

NS

NS

*

■*

NS

NS

p<.05

NS

pc.001

pc. 05

T+l

*•*■*-*■»•

*

T

o
"O

T-l

ii

CT

p =. lb

•a-***#

T+l
CM
T-l

NS

NS

NS

T

NS

p<.05

NS

T+l

*

p<.001

*■*■«■■*■*

NS

P
T-l

NS

NS

NS

T

NS

NS

pc.05

T+l

*

p<.05

pc.001

■^Insufficient data to make comparison
NS=No significance
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